iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) and Candel Therapeutics (NASDAQ:CADL – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.
Volatility and Risk
iTeos Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.
Profitability
This table compares iTeos Therapeutics and Candel Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iTeos Therapeutics | 9.02% | -4.42% | -3.83% |
| Candel Therapeutics | N/A | -75.60% | -44.60% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iTeos Therapeutics | $85.99 million | 5.13 | $96.65 million | ($0.80) | -15.40 |
| Candel Therapeutics | $62,000.00 | 559.74 | -$18.79 million | ($1.11) | -1.08 |
iTeos Therapeutics has higher revenue and earnings than Candel Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 18.2% of Candel Therapeutics shares are owned by institutional investors. 10.2% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 44.6% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and recommmendations for iTeos Therapeutics and Candel Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iTeos Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Candel Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
iTeos Therapeutics currently has a consensus price target of $36.33, indicating a potential upside of 194.91%. Candel Therapeutics has a consensus price target of $9.00, indicating a potential upside of 650.00%. Given Candel Therapeutics’ higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than iTeos Therapeutics.
Summary
iTeos Therapeutics beats Candel Therapeutics on 9 of the 13 factors compared between the two stocks.
About iTeos Therapeutics
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
